Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
NIRAPARIB 21,634 1,370 6.3% 4,892 994 65.7 yrs 98.5%
OLAPARIB 18,274 5,496 30.1% 3,471 760 62.3 yrs 79.9%
RUCAPARIB CAMSYLATE 8,240 448 5.4% 1,148 19 65.1 yrs 95.2%
TALAZOPARIB 1,477 278 18.8% 553 97 60.1 yrs 55.7%

Head-to-Head Comparisons

NIRAPARIB vs OLAPARIB NIRAPARIB vs RUCAPARIB CAMSYLATE NIRAPARIB vs TALAZOPARIB OLAPARIB vs RUCAPARIB CAMSYLATE OLAPARIB vs TALAZOPARIB RUCAPARIB CAMSYLATE vs TALAZOPARIB
← Back to Poly(ADP-Ribose) Polymerase Inhibitor [EPC] Class side effects →